Navigation Links
The SFJ Pharmaceuticals Group Announces Agreement With Pfizer to Co-develop Dacomitinib as First-Line Treatment for Patients With Advanced Non-small Cell Lung Cancer

SAN FRANCISCO, September 7, 2012 /PRNewswire/ --

Phase 3 Trial to be Conducted Across Sites in Asia and Europe

The SFJ Pharmaceuticals Group (SFJ), announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial of Pfizer's investigational pan-HER (pan-human epidermal growth factor receptor) inhibitor, dacomitinib (PF-00299804).  The trial, which will be conducted across multiple sites in Asia and Europe, will evaluate dacomitinib as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor (EGFR).

Under the terms of the agreement, SFJ will provide the funding and clinical development supervision to generate the clinical data necessary to support a registration dossier on dacomitinib for marketing authorization by regulatory authorities for the indication: First-line treatment of patients with locally advanced or metastatic NSCLC with EGFR activating mutations.  If approved for this indication, SFJ will be eligible to receive milestone payments and earn-out payments.

This is the second collaborative agreement between SFJ and Pfizer.  SFJ previously entered into an agreement with Pfizer to conduct a Phase 3 trial in Asia of Pfizer's Inlyta® (axitinib) for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma following nephrectomy.

"At SFJ, our mission is to accelerate the availability of new and innovative drugs into the world's major markets through co-development," said Robert DeBenedetto, SFJ's President & CEO.  "With this important, multi-national trial, we are pleased to continue our collaborative relationship with Pfizer and support the clinical development of a promising new agent for the treatment of lung cancer."

"Pfizer is committed to building innovative partnerships that enable us to advance our clinical development programs and deliver new cancer medicines to patients as efficiently as possible around the world," said Garry Nicholson, president and general manager, Pfizer Oncology. "Non-small cell lung cancer remains a difficult disease to treat despite recent advances, and Pfizer is evaluating dacomitinib in NSCLC across lines of therapy and a range of histologies and molecular subtypes.  By collaborating with SFJ on the continued clinical development of dacomitinib in this patient population, we hope to more immediately bring a new first-line therapy to patients in need."

Dacomitinib is an oral, once-daily, small molecule inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases.  It is being evaluated by Pfizer in a comprehensive clinical development program that includes two global, randomized Phase 3 clinical trials investigating its safety and efficacy as a second-line and refractory treatment for NSCLC.  Dacomitinib has not been approved by any regulatory agency.  

About the SFJ Pharmaceuticals Group
The SFJ Pharmaceuticals Group, which was formed in January of 2009 is a global drug development group of companies, which provides a unique co-development partnering model for some of the world's top pharmaceutical and biotechnology companies.  SFJ uses its financial strength and core team of pharmaceutical development experts to provide highly customized partnering models in which SFJ provides the funding and clinical development supervision, necessary to obtain regulatory approval for some of the most promising drug development programs of Pharmaceutical and Biotechnology companies. SFJ is backed by Abingworth, Clarus and Fintech, which are venture capital firms specializing in bio-pharmaceutical development. Collectively these venture capital firms manage over USD $2.5 billion in funding.

SOURCE SFJ Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
2. Jazz Pharmaceuticals Announces Participation At The 2012 Morgan Stanley Global Healthcare Conference In New York On September 11
3. Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
4. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
5. Global Markets for Membrane Technology for Pharmaceuticals
6. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
7. Jazz Pharmaceuticals Enters Definitive Agreement to Sell its Womens Health Business to Meda
8. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
9. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
10. Questcor Pharmaceuticals to Present at Investor Conferences in September
11. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Research . --> Clinical Cancer Research . ...
(Date:11/26/2015)... , November 26, 2015 --> ... to use SyMRI to find optimal contrast weighting of MRI ... metastases, and has signed a research agreement with SyntheticMR in ... hospital. Using SyMRI, it is possible to generate multiple contrast ... after the patient has left, thus making it possible to ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... to discuss bioavailability and the need to integrate dose form selection in early ... with OBN, the membership organization supporting and bringing together the UK’s emerging life ...
(Date:11/26/2015)... Aliso Viejo, CA (PRWEB) , ... November 26, ... ... X users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. ... custom style options. These classically-influenced trailer titles work with any font, giving users ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part of a ... ™ attracts volunteers together who want to combine talents and resources to help ... in the process. The non-profit launched its first major fundraiser on November 6, ...
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... ... launched offering factory direct sauna parts and accessories. , Sauna accessories help ... of the bather’s style and personality. From basic styles for the purist looking ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is donating ... Beat ” campaign. The partnership between the two groups began in 2014 with Vitalalert ... cause. , MAP International was founded in 1954 and is an international Christian-based health ...
Breaking Medicine News(10 mins):